Doxycycline inhibition of abdominal aortic aneurysm growth - a systematic review of the literature

Current Vascular Pharmacology

Volumn 9, Issue 4, 2011, Pages 471-478

  Dodd, Benjamin R ^a   Spence, Roy A ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Abdominal aortic aneurysm; Doxycycline; Matrix metalloproteinase

Indexed keywords

CYSTEINE PROTEINASE; DOXYCYCLINE; ELASTIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 25; MESSENGER RNA; NEUTROPHIL COLLAGENASE; STROMELYSIN; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANEURYSM SURGERY; AORTA; ARTICLE; BLEEDING; BLOOD VESSEL BIOPSY; CONCENTRATION RESPONSE; DISEASE COURSE; DRUG EFFECT; ENDOVASCULAR ANEURYSM REPAIR; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; MYCOSIS; NONHUMAN; OPERATION DURATION; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; TOOTH DISCOLORATION; TRANSCRIPTION REGULATION; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; AORTIC ANEURYSM, ABDOMINAL; CLINICAL TRIALS AS TOPIC; DOXYCYCLINE; HUMANS; MATRIX METALLOPROTEINASES; MEDICATION ADHERENCE; RESEARCH DESIGN;

EID: 79959961045     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111796197288     Document Type: Article

References (44)

1. Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg 2002; 39: 110-230.
2. Brewster DC, Cronenwett JL, Hallett JW Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg 2003; 37: 1106-17.
3. Rentschler M, Baxter T. Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture. Ann NY Acad Sci 2006; 1085: 39-46.
4. Fleming C, Whitlock EP, Beil TL, Lederle FA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the US Preventative Services Task Force. Ann Intern Med 2005; 142: 203-11.
5. Grange JJ, Davis V, Baxter BT. Pathogenesis of abdominal aortic aneurysm: update and look toward the future. Cardiovasc Surg 1997; 5: 256-65.
6. Dobrin PB, Mrkvicka R. Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc Surg 1994; 2: 484-8.
7. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2002; 105: 1641-9.
8. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases-2 and-9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-32.
9. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RW. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000; 11: 1345-52.
10. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA, Pearce WH. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997; 96: 2228-32.
11. Sapadin AN, Fleischmajer R. Tetracyclines: non-antibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-65.
12. Golub LM, Wolff M, Lee HM, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985; 20: 12-23.
13. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23: 336-46.
14. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998; 28: 1082-93.
15. Prall AK, Longo GM, Mayhan WG, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 2002; 35: 923-9.
16. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23: 483-8.
17. Kaito K, Urayama H, Watanabe G. Doxycycline treatment in a model of early abdominal aortic aneurysm. Surg Today 2003; 33: 426-33.
18. Sho E, Chu J, Sho M, et al. Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg 2004; 39: 1312-21.
19. Bartoli MA, Parodi F, Chu J, et al. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg 2006; 20: 228-36.
20. Turner GH, Olzinski AR, Bernard RE, et al. In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI. Circ Cardiovasc Imaging 2008; 1: 220-6.
21. Rees C. Table 5: Framework for critiquing quantitative research. 1995. In: Rees C, Taylor A, Mapleson W, Eds. PGCert/PGDip/MSc in Advanced Surgical Practice: Module 1AResearch 2001. Wales College of Medicine, Biology, Health and Life Sciences.
22. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17: 1-12.
23. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Ann N Y Acad Sci 1999; 878: 159-78.
24. Curci JA, Mao D, Bohner DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31: 325-42.
25. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34: 606-10.
26. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicentre study. J Vasc Surg 2002; 36: 1-12.
27. Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg 2003; 38: 1376-83.
28. Ding R, McGuiness CL, Burnand KG, Sullivan E, Smith A. Matrix metalloproteinases in the aneurysm wall of patients treated with low-dose doxycycline. Vascular 2005; 13: 290-7.
29. Hackmann AE, Rubin BG, Sanchez LA, Geraghty PA, Thompson RW, Curci JA. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 2008; 48: 19-26.
30. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, Lindeman JHN. Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 2009; 49: 741-9.
31. Lindeman JHN, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic Tcells. Circulation 2009; 119: 2209-16.
32. Bedi A, Fox AJS, Kovacevic D, Deng X-h, Warren RF, Rodeo SA. Doxycycline-mediated inhibition of matrix metalloproteinases improves healing after rotator cuff repair. Am J Sports Med 2010; 38: 308-17.
33. Singh K, Bonaa KH, Solberg S, Sorlie DG, Bjork L. Intra-and interobserver variability in ultrasound measurements of abdominal aortic diameter. The Tromso Study. Eur J Vasc Endovasc Surg 1998; 15: 497-504.
34. MacSweeney ST, Ellis M, Worrell PC, Greenhalgh RM, Powell JT. Smoking and growth rate of small aortic aneurysms. Lancet 1994; 344: 651-2.
35. Shantikumar S, Ajjan R, Porter KE, Scott DJ. Diabetes and the abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2010; 39: 200-7.
36. Vega de Ceniga M, Gomez R, Estallo L, Rodriguez L, Baquer M, Barba A. Growth rate and associated factors in small abdominal aortic aneurysms. Eur J Vasc Endovsc Surg 2006; 31: 231-6.
37. Baxter BT. Regarding use of doxycyline to decrease the growth rate of abdominal aortic aneurysms. J Vasc Surgery 2001; 34: 757-8.
38. Wolf YG, Hill BB, Rubin GD, Fogarty TJ, Zarins CK. Rate of change in abdominal aortic aneurysm diameter after endovascular repair. J Vasc Surg 2000; 32: 108-15.
39. Miyaki T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res 2009; 83: 436-43.
40. Bertges DJ, Zwolak RM, Deaton DH, et al. Current hospital costs and Medicare reimbursement for endovascular abdominal aortic aneurysm repair. J Vasc Surg 2006; 37: 272-9.
41. EVAR trial participants. Endovascular aneurysm repair vs. open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomized controlled trial. Lancet 2005; 365: 2179-86.
42. Colditz GA, Miller JN, Mosteller F. How study design affects outcome in comparisons of therapy. Stat Med 1989; 8: 411-54.
43. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
44. Van Kuijk JP, Flu WJ, Witteveen OP, Voute M, Bax JJ, Poldermans D. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms. J Cardiovasc Surg 2009; 50: 599-609.